Melanoma is noted for its alarming increase in incidence, especially amongst the young, aggressive clinical behavior and propensity for lethal metastasis, illustrating an urgent need for new treatment strategies for this disease. Despite the bleak clinical and epidemiological picture, genetic analysis has uncovered key driver oncogenes in melanoma such as mutationally activated BRAF. Indeed, when the BRAFV600E oncoprotein is pharmacologically inhibited with vemurafenib, BRAF mutated melanoma patients, even those with widely disseminated, metastatic disease, have enjoyed dramatic tumor regression coupled with significant health improvement. However, since not all BRAF mutated melanoma patients respond to vemurafenib and, those that do, generally relapse with lethal drug resistant disease, the paradigm of melanoma therapy is evolving towards rationally-targeted combinations of pathway-targeted inhibitors acting against BRAFV600E and cooperating signaling modules such as the PI3'-kinase->AKT pathway. Indeed, despite vemurafenib's clinical success and our growing scientific knowledge of the melanoma cell's inner workings, the challenge remains how best to employ BRAF inhibitors for melanoma therapy to: 1. Maximize therapeutic benefit;2. Minimize emergence of lethal drug resistant disease;and;3. Mitigate potentially harmful side effects. Consequently, the long-term, overarching goal of this research is to design BRAF inhibitor-based combination therapies that enhance the overall response rate and the depth of each patient's primary anti-tumor response and extend indefinitely the duration of remission of patients with BRAF mutated melanoma in collaboration with colleagues in the UCSF Melanoma Clinic. Towards these goals, the short-term aims of this proposal are to employ state-of-the-art genetically engineered mouse (GEM) models, bona fide human melanoma cells and a portfolio of clinically relevant pathway-targeted inhibitors to elucidate the molecular mechanism(s) of BRAFV600E/PI3'- kinase pathway cooperation in melanomagenesis and the consequences of combined pathway-targeted blockade in the pre-clinical setting.
In Aim 1, GEM models will be used to probe the importance of PI3'- kinase->AKT signaling in cooperating with oncogenic BRAFV600E in converting normal melanocytes to metastatic melanoma cells.
In Aim 2 the superiority of combined versus single agent inhibition of BRAFV600E or PI3'-kinase in promoting tumor regression will be evaluated using GEM models of BRAFV600E-initiated melanoma. To complement analysis of mouse melanoma specimens in Aim 2, a panel of bona fide human BRAFV600E expressing melanoma cell lines will be employed in Aim 3 to elucidate molecular mechanism(s) by which BRAFV600E cooperates with PI3'-kinase->AKT signaling in regulating the melanoma cell division cycle and/or apoptosis through effects on protein synthesis. When completed, these studies will provide the mechanistic foundation for the development of robust and rational, pathway-targeted combination therapeutic strategies to increase both the quantity and quality of life of patients with BRAF mutated melanoma.

Public Health Relevance

Melanoma is an increasingly common and highly aggressive form of cancer diagnosed in ~132,000 patients and responsible for ~20,000 deaths per year worldwide. Recently a new drug, vemurafenib, has shown great promise in the treatment of the ~50% of patients whose melanoma is driven by a mutated BRAF oncogene. Leveraging the success of vemurafenib, we propose here to employ state-of-the-art experimental systems to design and evaluate new, rationally targeted combination therapeutic strategies with the long-term goal of curing patients with melanoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA176839-01
Application #
8514887
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Alley, Michael C
Project Start
2013-04-01
Project End
2018-03-31
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
1
Fiscal Year
2013
Total Cost
$362,392
Indirect Cost
$131,385
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Deuker, Marian M; Marsh Durban, Victoria; Phillips, Wayne A et al. (2015) PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov 5:143-53
Cooper, Zachary A; Juneja, Vikram R; Sage, Peter T et al. (2014) Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2:643-54
Luo, Xi; Mitra, Devarati; Sullivan, Ryan J et al. (2014) Isolation and molecular characterization of circulating melanoma cells. Cell Rep 7:645-53
Silva, Jillian M; Bulman, Christina; McMahon, Martin (2014) BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation. Mol Cancer Res 12:447-63
Deuker, Marian M; McMahon, Martin (2014) Cancer biology: Enzyme meets a surprise target. Nature 510:225-6
Holderfield, Matthew; Deuker, Marian M; McCormick, Frank et al. (2014) Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 14:455-67
Silva, Jillian M; McMahon, Martin (2014) The fastest Western in town: a contemporary twist on the classic Western blot analysis. J Vis Exp :e51149
Das Thakur, Meghna; Salangsang, Fernando; Landman, Allison S et al. (2013) Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494:251-5